Indeed here we show both in vitro and in an in vivo xenograft model that combined treatment with A3 and A4 antibodies is able to more potently induce receptor degradation and as a result to more potently sinergize with the BRAF/MEK inhibitors in tumor growth impairment and induction of apoptosis. Here, BRAF is linked to neoplasm.